# Paclitaxel, Carboplatin Plus Bevacizumab in Pretreated, Advanced or Metastatic Non Small Cell Lung Cancer

> **NCT00753909** · PHASE2 · COMPLETED · sponsor: **Hellenic Oncology Research Group** · enrollment: 50 (actual)

## Conditions studied

- Non Small Cell Lung Cancer

## Interventions

- **DRUG:** Carboplatin
- **DRUG:** Bevacizumab
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT00753909
- **Lead sponsor:** Hellenic Oncology Research Group
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-11
- **Primary completion:** 2016-10
- **Final completion:** 2016-10
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2016-10-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00753909

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00753909, "Paclitaxel, Carboplatin Plus Bevacizumab in Pretreated, Advanced or Metastatic Non Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00753909. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*